
æ¥æ¬è èåŠäŒã2021幎7æã«å ¬éããã¢ã³ã±ãŒãçµæãšæè¿è©±é¡ã®è«æ
ãªã³ã©ã€ã³ãžã£ãŒãã«ãCureusãïŒãã¥ãªã¢ã¹ïŒã§å ¬éãããæ¥æ¬äººå»åž«ã°ã«ãŒãã«ããè«æããã¢ã¡ãªã«ã®ç¬ç«ç³»ã¡ãã£ã¢ãSLAYãã§åãäžããããããšãXãnoteã®èšäºã§ç¥ããŸããããã®è«æã®å 容ã«é¢é£ããéå»èšäºãæãèµ·ããã€ã€ãæ°ã«ãªã£ãããšãåãäžããŸãã
è«æãšèšäºã®å 容
ãSLAYãã§åãäžããããã®ã¯ãé 倩å 倧åŠå»åŠéšé屿µŠå®ç é¢ è é«è¡å§å ç§ æ¢ æŸ€ç±äœ³åæ°ããçºè¡šãããA Series of Glomerular Diseases That Developed After COVID-19 Vaccinationããšããè«æã§ãã
ã³ããã¯ã¯ãã³æ¥çš®åŸã«çºçããã糞çäœçŸæ£ãã«é¢ããŠèª¿æ»ãè¡ããæ»èªãçµãŠ2025幎3æ24æ¥ã«å ¬éãããŸããã
ã糞çäœãã«ã€ããŠã¯ãäžèšããåŒçšããŸãã
æ¥æ¬è èåŠäŒã«ãããšããè èã®éèŠãªåãã®ã²ãšã€ã«ãè¡æ¶²äžã®èå»ç©ãå¡©åããéããå°¿ãšããŠèº«äœã®å€ã«æåºããããšããããŸãããã®åããããŠããã®ã糞çäœããšã®ããšã
æ¢ æŸ€æ°ãããããªã£ã調æ»ã®å¯Ÿè±¡è ã¯ã2021ïŠ1æãã2022ïŠ12æãŸã§ã«å葉çã®é 倩å å€§åŠæµŠå®ç é¢ã«ãããŠåéãããã³ããã¯ã¯ãã³æ¥çš®åŸã«è¡ïŠœãŸãã¯ã¿ã³ãã¯ïŠœãåãã24æ³ïœ66æ³ã®æ£è ïŒæ¥æ¬äººïŒ30åã22åããã¡ã€ã¶ãŒç€Ÿè£œã8åãã¢ãã«ã瀟補ã®ã³ããã¯ã¯ãã³ãæ¥çš®ã
çµæã¯ãã³ããã¯ã¯ãã³æ¥çš®åŸãè çæ€ã«ããæ°ãã«ç³žçäœçŸæ£ãšèšºæãããæ£è ã¯26åããã®ãã¡20åãIgANïŒIgAè çïŒãIgANã®æ²»ï§æŽããã4åã®æ£è ã¯ã異垞ã®å¢æªãšçŸæ£ã®åçºãçµéšãèçŒçè¡ïŠœã¯ã22åã§èгå¯ããããšã®ããšã
è«æã確èªããŸãããããSLAYãã®ãJapan Issues Alert as Deadly Kidney Failure Surges in Covid-VaxxedãïŒã³ããã¯ã¯ãã³æ¥çš®è ã«ãããèŽæ»æ§è äžå šã®æ¥å¢ãåããæ¥æ¬ãèŠåãçºä»€ïŒãšããã¿ã€ãã«ã¯ããã¹ãªãŒãããªãšæããŸããã
ããªãæåŸ ããŠèªãã§ã¿ãã®ã§ããã30åã調æ»ããçµæãªã®ã§æ¥å¢ãšããæãã§ããªãããèŠåããšããã»ã©ã®ããšã¯æžãããŠããŸããã
çµè«
COVIDâ19ã¯ã¯ãã³ã«é¢é£ããé節ãªå¯äœçšã®å¯èœæ§ã¯çšã§ããããããªãããç§ãã¡ã®ã³ããŒãã§ã¯ãCOVIDâ19 mRNAã¯ã¯ãã³é¢é£ã®ç³ž
çäœçŸæ£ã®çãããã€ãå ±åãããŠããŸãããããã®çæçãªå¯äœçšã¯ã転垰ã¯ï¥Œå¥œã§ããããã«ïšããŸãããäžéšã®æ£è ã§ã¯é節ãªè æ©èœã®æªåãšããããŒãŒã¬ãã«ã®ã¿ã³ãã¯ïŠœãçºçŸããŸãããmRNAã¯ã¯ãã³èªçºæ§è çŸæ£ã®çºçã¡ã«ããºã ã¯äŸç¶ãšããŠï¥§æã§ãããã®çç©åŠçã¡ã«ããºã ãè§£æããæ£ç¢ºãªå æé¢ä¿ãç¹å®ããã«ã¯ããããªãç ç©¶ãå¿ èŠã§ãã
ãé節ãªå¯äœçšã®å¯èœæ§ã¯çšããšæžãããŠããã®ãèŠããšãçŸå®ãšã®ãºã¬ãæããŸããã³ããã¯ã¯ãã³æ¥çš®åŸã®äºé²æ¥ç𮿿žå¶åºŠã§èªå®ãããæ»äº¡è æ°ã¯ã5æ2æ¥æç¹ã§1006ä»¶ã§ãã
5æ2æ¥å ¬é

æ»äº¡ä»¥å€ã§ããäŸãã°éå»ã«åãäžãã什å5幎11æ13æ¥å ¬éåã«ãè çŸæ£ã®èªå®äºäŸã¯è€æ°ãããŸããã



äžèšã®èšäºã§ããè çŸæ£ã®å¢æªã«ã€ããŠåãäžããŸããã
å°ã話ãéžããŸããããã®ææžå¶åºŠã¯ãå³å¯ãªå»åŠçãªå æé¢ä¿ãŸã§ã¯å¿ èŠãšãããæ¥çš®åŸã®çç¶ãäºé²æ¥çš®ã«ãã£ãŠèµ·ããããšãåŠå®ã§ããªãå Žåã察象 ãšã®èãæ¹ã«åºã¥ã審æ»ããŠãããšæžãããŠããããšãããå ã¯ã¯ãã³æ åœå€§è£ã¯äžèšã®ããã«èšã£ãŠããŸããã
å¯åå¿çãå ±åå¶åºŠã§ã¯å æé¢ä¿äžæãšãããŠããäºäŸã§ããææžãããå Žåããããæ»äº¡äºäŸã®èªå®ãè¡ãããããšã¯ããã¯ã¯ãã³æ¥çš®ãåå ã§æ»äº¡ãããããšãšã¯ç°ãªããŸãã
WHOã®è©äŸ¡ã§ã¯ãpossible以äžïŒäžèšåç §ïŒã«é¢ããŠã¯å æé¢ä¿ã®åŒ·ãã瀺ããŠããã®ã§ãpossible以äžã¯å æé¢ä¿ããããšããããšã以åãèšåºè¬åŠå士ã®å å æå éæ°ã説æããŠããŸããã
The use of the WHO-UMC system
for standardised case causality assessmentã2018幎4æ6æ¥

ãã®åºæºã«åœãŠã¯ããã°ææžå¶åºŠã§èªå®ãããäºäŸã¯ãå æé¢ä¿ãããããšãããéå»ã®å€äŸããããæ³çã«ãå»åŠçã«ããææžå¶åºŠã§èªãããããšããããšã¯å æé¢ä¿ãèªãããããšèããŠãããšã®ããšã§ããïŒäžèšåç
§ïŒã
åè¿°ã®è«æã«ã¯ãmRNAã¯ã¯ãã³èªçºæ§è çŸæ£ã®çºçã¡ã«ããºã ã¯äŸç¶ãšããŠï¥§æã§ãããã®çç©åŠçã¡ã«ããºã ãè§£æããæ£ç¢ºãªå æé¢ä¿ãç¹å®ããã«ã¯ããããªãç ç©¶ãå¿ èŠã§ãããšæžãããŠããŸãããšããããšã¯ä»ã®æ®µéã§ãå³å¯ãªå æé¢ä¿ãç¹å®ããããšãªã©ã§ããªãã§ãããã
ãµãªããã€ãã®å¯äœçšã«ã€ããŠã¯ãã¡ã«ããºã ãè§£æããã®ã¯çŽ50幎åŸã§ããïŒäžèšåç §ïŒã
æ¿åºã¯ãã¡ã«ããºã ãè§£æã§ããŠããªããã®ãå®å šã ãšèšã£ãŠåœæ°ã«å§ããŠãããŠãå¥åº·è¢«å®³ã«ãã£ã人ã«ã¯ãå æé¢ä¿äžæããšèšã£ãŠè²¬ä»»éããããŠããããšã«ãªããŸãã
ãSLAYãã®èšäºã«æ»ããŸãã
ãSLAYãã®èšäºã¯ãéæ¿ãªã¿ã€ãã«ã«ããŠã¢ã¯ã»ã¹æ°ãå¢ããããšããæãã§ãå 容ãšãºã¬ããããšæããŸãããã§ããããèšäºãèªãã ã ãã§æ¡æ£ããã«ãå ã®è«æã確èªããããšã倧åã ãšæããŸãã
ãSLAYãã®èšäºã§ãã1ç¹æ°ã«ãªã£ãã®ã¯ããThey published the findings of their peer-reviewed study in the prestigious medical journal Cureus.ããšããéšåããCureusãã®ããšããæš©åšããå»åŠéèªããšæžããŠããŸãããäžèšã®èšäºã«ã¯ãã¹ã¿ã³ãã©ãŒã倧åŠã®ç¥çµå€ç§å»ãžã§ã³ã»ã¢ãã©ãŒæ°ãèæ¡ããçäŸå ±åãå ±æãããã©ãããã©ãŒã ãã ãšæžãããŠããŸãã
æ¢åã®å»åŠéèªã§ã¯éèŠãããŠããªãã£ãæ£è ã®çç¶ã蚺æçµæãæ²»çåå¿ãªã©ã詳现ã«èšããçäŸå ±åãå ±æã§ããå ŽãšããŠè©äŸ¡ãããŠãããšã®ããšãªã®ã§ããæš©åšããå»åŠéèªããšã¯éãããã«æããŸãã
å人ïŒå»åž«ïŒã®ããã°ãããã€ã確èªããŸãããããCureusãã¯ããŒãã«ãäœãã®æçš¿å ãšããŠæåŸ ãããŠãããšããæãã§ããã
ç§ã¯ããããã£ãéšåãæ£ç¢ºã«æžããŠããªãèšäºããã®ãŸãŸä¿¡çšããããšã¯ã§ããŸããããã¡ããšèª¿ã¹ãã«èšäºãæžãèšè ïŒã©ã€ã¿ãŒïŒãªã®ããªãšæãããã§ãã
ãã®è«æã玹ä»ããŠããæ¥æ¬ã®ã¡ãã£ã¢ã¯ãªãããã§ããããããèªãã§ç§ã¯ããã¢ã³ã±ãŒããæãåºããŸããã
ããã¯ãæ¥æ¬è èåŠäŒã2021幎7æ1æ¥ä»ã§å ¬éããã¢ã³ã±ãŒãçµæã§ãã
æ¥æ¬è èåŠäŒã®ã¢ã³ã±ãŒã
æ¥æ¬è èåŠäŒã¯ãè©è°å§å¡581åïŒå ç§ã»è èå ç§339åã382æœèšïŒã«ãããªã£ããCOVID-19ã¯ã¯ãã³æ¥çš®ãšèçŒçè¡å°¿åºçŸã®é¢é£æ§ã«é¢ãã調æ»ç ç©¶ãïŒ2021幎6æ2æ¥ã6æ26æ¥ïŒãããIgAè çæ£è ã§ã¯ã¯ã¯ãã³æ¥çš®åŸã«èçŒçè¡å°¿ãåºçŸããå¯èœæ§ãããããšãææ¡ããŠããŸããïŒäžèšåç §ïŒã
ã¢ã³ã±ãŒãçµæã¯äžèšã§ã確èªãã ããã
COVID-19ã¯ã¯ãã³ãšèçŒçè¡å°¿ã®é¢é£ã«ã€ããŠã®èª¿æ»
ãã¢ã³ã±ãŒãçµæãŸãšããïŒæéïŒ2021幎6æ2æ¥ã6æ26æ¥ïŒ
2021幎7æ1æ¥ãšããæ©ãæ®µéã§ãã³ããã¯ã¯ãã³æ¥çš®ãšè¡å°¿ã«é¢ä¿ãããããšãããã£ãŠããã®ã«ãåœæ°ã®å€ãã¯ç¥ããªãã£ããšæããŸããå»åž«ã®å€ãããç¥ããªãã£ãã®ã§ã¯ãªãã§ããããã
ãã®æç¹ã§ãã£ãšãã£ãããšãã®äºå®ãåœæ°ã«ç¥ãããŠããã°ãè çŸæ£ã®ãã人ããã®å¯èœæ§ãããäººã¯æ¥çš®ãããªããšããéžæãã§ãããããããŸããã
ãCureusãã«å ¬éãããè«æã¯ãäžèšã®ããã«ãŸãšããããŠããŸãã
COVID-19ã¯ã¯ãã³ã«é¢é£ããé節ãªå¯äœçšã®çºççã¯äœããããããªãããæ¬ã³ããŒãã§ã¯COVID-19 mRNAã¯ã¯ãã³é¢é£ç³žçäœçŸæ£ã®çäŸãè€æ°å ±åãããŠãããçæçãªè»¢åž°ã¯è¯å¥œã«èŠãããã®ã®ãäžéšã®æ£è ã§ã¯è æ©èœã®éç¯€ãªæªåãšããããŒãŒã¬ãã«ã®ã¿ã³ãã¯å°¿ãçºçŸãããmRNAã¯ã¯ãã³èªçºæ§è çŸæ£ã®çºçæ©åºã¯äŸç¶ãšããŠäžæã§ãããæ ¹æ¬çãªçç©åŠçæ©åºãè§£æããæ£ç¢ºãªå æé¢ä¿ãç¹å®ããã«ã¯ããããªãç ç©¶ãå¿ èŠã§ããã
ãmRNAã¯ã¯ãã³èªçºæ§è çŸæ£ã®çºçæ©åºã¯äŸç¶ãšããŠäžæã§ããããæ ¹æ¬çãªçç©åŠçæ©åºãè§£æããæ£ç¢ºãªå æé¢ä¿ãç¹å®ããã«ã¯ããããªãç ç©¶ãå¿ èŠã§ããããšæžãããŠãããæ¿åºã¯ãããªãã®ã®æ¥çš®ããå®å šãã ãšèšã£ãŠå§ããŠããã®ã§ãã
æ¬æ¥ãªãããããã£ãç ç©¶ãååã«ããŠããæ¥çš®ãéå§ããã¹ãã§ã¯ãªãã®ã§ããããã
ãã£ãããšå®å šæ§ã確èªããã«æ¥çš®ãå§ããŠãå¥åº·è¢«å®³ã«ãã人ã倿°åºãŠããç ç©¶ãããªããŠãé çªãããããã§ãããç·æ¥äºæ ã ã£ããã仿¹ãªãããšãããããããŸããããããã§ãããªããå®å šæ§ã確èªã§ããŠããªãããšããã¡ããšèª¬æããã¹ãã§ãããã®ãããªãªã¹ã¯ãç¥ã£ãŠããã®ã«ååã«èª¬æããã«ãæ¥çš®ãå§ãã人ãã¡ã®çœªã¯éããšæããŸãããŸããæ¥çš®ã«é¢ããå»çåŸäºè ãªã®ã«ããã®ãããªæ å ±ã調ã¹ãããšããªãã£ã眪ãéããšç§ã¯æããŸãã
ååŽçã®è³æãªã©ãèŠããšãæ¥çš®åŸã®è çŸæ£ã軜çãªãããããã¯å埩ã§ããã°ãããšæã£ãŠããããã«ãæããŸããè çæ€ã¯ãšãŠãçãæ€æ»ã§ããã¹ããã€ãã䜿ã£ãæ²»çã¯ãæ§ã ãªå¯äœçšããããŸããæ¥çš®ããªããã°ããã®ãããªæ€æ»ãæ²»çãããã«æžãã 人ãããã¯ãã§ãããã®éžæãããããã«ã¯æ å ±ãå¿ èŠã§ãããå»åž«ãããã®ãããªæ å ±ãåŸããã人ã¯ã©ããããããã®ã§ããããã
远跡調æ»ã¯ãããŠããã®ãïŒ
ããã«è«æã«ã¯ããçæçãªçµæã¯è¯å¥œã§ããããã«èŠããããå°æ¥ã®äºåŸãäºæž¬ããã«ã¯é·æçãªè¿œè·¡èª¿æ»ãäžå¯æ¬ ããšãæžãããŠããŸãã
ååŽçã®ãµã€ãã§å ¬éãããŠãããå¯åå¿çãã®å ±åãã«ã¯ã10代ã®äºäŸã倿°å ±åãããŠããŸããããããã®è¿œè·¡èª¿æ»ã¯ãããŠããªãã®ã§ããããã
å ±åå»åž«ãããã®ãªãã远跡調æ»ãããããšæãã°ã§ããã¯ãã§ãããã®æç¹ãã远跡ããŠããã¯ãããªãã®ããŒã¿ãéãŸã£ãŠããã¯ããªã®ã«ãåè¿°ã®è«æããã¯ãã®ãããªããŒã¿ãããããã«ã¯æããŸããã
ã¢ã³ã±ãŒã調æ»ãè¡ã£ãæ¥æ¬è
èåŠäŒã®åœ¹å²ãšã¯ãäœãªã®ã§ããããã
ãã£ããæ©æã«è¡å°¿ãšã®é¢ä¿ã«æ°ã¥ããã®ã«ããªãããããã£ãšåºãç¥ãããããšããªãã£ãã®ã§ããããããµã€ãã§å
¬éããŠããã ãã§ã¯ãç¥ãããããšã«ãªããªãã§ãããã
è çŸæ£ã§éé¢ããŠããæ£è ããã®äžã§ãæ åœå»åž«ãããã®ãããªã¢ã³ã±ãŒãçµæãåºãŠããããšãç¥ããããŠãã人ã¯ã©ããããããã®ã§ããããã